Inicio
Publications Oncology
| Title | Authors/Publication Reference |
|---|---|
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. | Tannock IF, et al./ N Engl J Med. 2004;351(15):1502-12. |
| Phase II study with the combination of capecitabine (C) and vinorelbine i(V) n metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes | L. Estevez et al. / ASCO-2004 |
| Phase II study of capecitabine a (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage) | M. Bellet et al./ ASCO-2004 |
| Phase II study with the combination of capecitabine (C) and vinorelbine i(V) n metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes | L. Estevez et al./ ESMO-2004 |
| Phase II study of capecitabine a (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage) | M. Bellet et al./ ESMO-2004 |
| Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile.Early results | M. Bellet et al./ ASCO-2005 |
| Docetaxel followed by capecitabine as first-line chemotherapy in metastatic breast cancer patients: preliminary results | Dr. Bayo et al./ ASCO-2005 |
| Induction (I) or consolidation (C) chemotherapy with docetaxel (D) and gemcitabine (G) plus concomitant chemoradiotherapy (CT/TRT) with docetaxel and carboplatin (Cb) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p).Initial report of the randomized phase II trial SLCG 0008 | P. Garrido & GECP/ ASCO-2005 |
| Phase II/III Trial Induction Chemotherapy (ICT) with Cisplatin/5-Fluoruracil (PF) vs. Docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for Unresectable Locally Advanced Head and Neck Cancer(LAHNC) | R. Hitt & TTCC/ ASCO-2005 |
| Toxicity and health-related quality of life (HRQoL) in node negative breast cancer (BC) patients (pts)receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC ( 5-fluoruracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors ( GF) to TAC. GETCAM Study 9805 | M. Martín & GEICAM/ ASCO-2005 |
| Pharmacogenetic study in patients (pt) with metastatic breast (BC) and colorectal cancer (CRC) treated with capecitabina (C) | Dr. Alba et al./ ASCO-2005 |
| Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study | Dr. Sastre et al./ JClinOncol 2005 May 20; 23 (15): 3545-3551 |
| Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer | Dr. Quintela-Fandino/Dra. Grávalos/ Anticancer Drugs. 2005 Jan;16(1):31-8. |
| Guides for adjuvant treatment of colon cancer | Aranda E./ Clin Transl Oncol 2006; 8(2):98-102 |
| A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. | Navarro M./Int J Radiat Oncol Biol Phys 2006 Sep 1; 66(1):201-5 |
| Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). | R. Hitt et al. / ASCO-2006 |
| Estudio asistencial de la combinación de Capecitabina con Carboplatino administrados cada dos semanas en pacientes con cancer de mama metastasico | I. Chacon et al./ ASCO 2006 |
| Docetaxel (T) followed by capecitabine (X) as first-line chemotherapy in patients (pts) with metastatic breast cancer (MBC): Preliminary findings from a phase II study | JL. Bayo et al./ ASCO 2006 |
| Phase II study of capecitabine (X) + docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates. | M. Bellet et al./ ASCO-2006 |
| Phase II study of capecitabine (X) in combination with vinorelbine (N) in patients (pts) with pretreated metastatic breast cancer (MBC). | N. Batista et al/ ASCO-2006 |
| Estudio Fase II randomizado del tratamiento continuo versus tratamiento estandar con capecitabina en pacientes con cáncer de mama metastásico. | M. Martin et al./ ESMO-2006 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ XI Congreso nacional SEOM, Clin Transl Oncol, vol9, extraordinary 2, Oct 2007: P-141 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ ASTRO 49th Annual Meeting; 2007 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ 12th WCLC Journal of Thoracic Oncology, vol2, nº8, supplement 4: P3-113 |
| Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patientes with unresectable NSCLC: a prospective randomized phase II study | E. Martinez et al./ ASCO 2008 |
| Adjuvant Chemotherapy with sequential or concurrent Anthracycline and Docetaxel: Breast International Group 02-98 randomized trial | Francis P/J Natl Cancer Inst 2008;100:121-133 |
| A multicenter phase II study to evaluate the sequential Docetaxel followed by Capecitabine treatment in anthracycline pretreated HER-2 negative patients with metastatic breast cancer | J. Bayo et al./ JClin Transl Oncol 2008 |
| A phase II study of weekly vinorelbine and trastuzumab in patients with HER-2 positive metastatic breast cancer | Bayo-Calero JL et al./ Clin Breast Cancer 2008 Jun; 8(3): 264-8 |
Randomized study of weekly irinotecan lus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5 fluorouracil/leucovorin (FOLFIRI), as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish cooperative group for the treatment of digestive tumors study | E. Aranda/ Ann. Onc., February 2009; 20: 251 - 257 |
Final results of a randomized Phase III trial comparing induction chemotherapy (ICT) with cisplatin/5-FU (PF) or docetaxel/cisplatin/5-FU (TPF) followed by chemoradiotherapy (CRT)versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) | Dr Hitt Ret al.& Spanish Head and Neck Cancer Cooperative Group, Spain/ ASCO-2009 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group | P Garcia-Alfonso et al./ Br J Cancer 2009; 101: 1039–1043. |
| Activity of a multitargeted, chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal cell carcinoma: a phase II study (SOGUG-02-06) | Dr Bellmunt/The Lancet Oncology 2010 |
| "Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study" | C Fernández-Martos et al/J Clin Oncol 2010 |
| Phase II Study Of Bevacizumab + Oxaliplatin Plus Capecitabine Followed By Bevacizumab + Erlotinib As First-Line Treatment In Metastatic Colorectal Cancer | A Muñoz et al. ASCO 2010; Abstract No: 442 |
| Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO trial | J. Tabernero & Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Spain. ASCO 2010; Abstract No: 3501 |
| Phase I study of Sorafenib plus Ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) Study | X. Garcia del Muro et al. ASCO 2010; Abstract No: 10024 |
| Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer | J. Feliu et al. Br J Cancer 2010 May 11;102(10):1468-73. |
| Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment | J. Martinez-Trufero et al. Br J Cancer 2010 May 18; 102 (12): 1687 – 1691 |
| Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer | Cobo M et al. J Clin Oncol 2007; 25;19:2747-2754 |
| Activity of a multitargeted, chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal cell carcinoma: a phase II study (SOGUG-02-06) | Dr Bellmunt/The Lancet Oncology 2010;11 (4):350-357 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer | P Garcia-Alfonso et al. British Journal of Cancer (2010) 103, 1524 – 1528 |
| Predictive response factors in an open, non-randomized, phase II study of a combination of bevacizumab and sequential chemotherapy as preoperative treatment in patients with operable HER-2 negative breast cancer | P. Sánchez-Rovira et al. SABCS 2010; Abstract No: 851233 |
| First analysis of the value of Circulating Epithelial Tumor Cells and Circulating Endothelial Cells (CTCs/CECs) in patients with HER-2 negative locally advanced or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first line therapy (AVALUZ trial) | L. Manso et al. SABCS 2010; Abstract No:P3-02-11 |
| Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer | M. Martin et al. N Engl J Med 2010; 363;23:2200-2210 |
| Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study | A. Abad et al./ Acta Oncol. 2008; 47: 286-292 |
IMAGING: looking for imaging, molecular, and dynamic biomarkers to predict response to bevacizumab-based neoadjuvant therapy. Preliminary findings on tumor hypoxia and proliferation rate assessed by positron emission tomography (PET) | López Vega J. et al. VIII simposium Internacional GEICAM 2011 |
| Phase II study of bevacizumab in combination with temozolomide as treatment of patients with recurrent glioblastoma multiforme: preliminary anaysis of toxicity | Sepulveda J et al. European Multidisciplinary Cancer Congress- ECCO 2011; Abstract no. 8.751 |
| Recommendations and Expert Opinion on the Treatment of Locally Advanced Rectal Cancer in Spain | Grávalos C et al. Clin&Transl Oncol. 2011 Dec;13(12):862-8. |
| Recommendations and Expert Opinion on the Adjuvant treatment of Colon Cancer in Spain | Viéitez JM et al. Clin&Transl Oncol. 2011 Nov;13(11):798-804. |
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial | Rosell R et al. Lancet Oncology 2012; January 26. DOI:10.1016/S1470-2045(11)70393-X |
| Randomized, phase II trial comparing continuous versus intermittent capecitabine monotherapy for metastatic breast cancer (MBC). | Martin M. et al. ASCO 2011.Oral communication. J Clin Oncol 2011; 29 (suppl; abstr 1008) |
| Bevacizumab changes in patients with naïve, stage II-III breast cancer assessed by 18F-fluoromisonidazole and 18F-fluorotymidine PET-CT. | Boni V et al. ASCO 2011. Oral communication; J Clin Oncol 2011;29 (Suppl; abstr 2529) |
| Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. | Rosell R et al. ASCO 2011. Oral communication; J Clin Oncol 2011; 29 (suppl. Abstr 7503) |
| Abiraterone and Increased Survival in Metastatic Prostate Cancer | de Bono JS et al. N Engl J Med 2011; 364 (21): 1995-2005 |
